• In early May 2026, Rhythm Pharmaceuticals reported first-quarter revenue of US$60.11 million and a net loss of US$55.64 million, while also securing European Commission approval to expand IMCIVREE (setmelanotide) for acquired hypothalamic obesity and presenting longer-term efficacy and safety data across pediatric and adult populations.
• The new data presentations and broadened regulatory label for setmelanotide highlight growing clinical evidence in rare neuroendocrine obesity disorders and expand Rhythm’s addressable patient pool in both the US and Europe.
• We’ll now examine how the expanded EU approval for IMCIVREE in acquired hypothalamic obesity may reshape Rhythm’s existing investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.

Rhythm Pharmaceuticals Investment Narrative Recap

To own Rhythm Pharmaceuticals, you need to believe setmelanotide can support a focused rare-disease franchise while the company narrows substantial losses and manages funding needs. The expanded EU approval for acquired hypothalamic obesity reinforces the key near term catalyst of broader IMCIVREE adoption, but does not remove the immediate risk that continued operating losses and R&D spending could lead to further dilution via capital raises.

The most directly relevant update is the European Commission’s expanded marketing authorization for IMCIVREE in acquired hypothalamic obesity, supported by the Phase 3 TRANSCEND data showing a placebo adjusted BMI reduction of 19.8%. This broadens Rhythm’s potential treated population on both sides of the Atlantic and ties closely to the current investment focus on execution in new indications and markets while the company remains loss making.

Yet alongside this expanded label, investors should be aware that ongoing net losses and the recent US$200 million ATM filing could...

Rhythm Pharmaceuticals’ narrative projects $873.3 million revenue and $209.1 million earnings by 2029.

Uncover how Rhythm Pharmaceuticals' forecasts yield a $137.67 fair value, a 52% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$127 to US$480 per share, highlighting very different return expectations. Against that wide range, Rhythm’s continued operating losses and reliance on future IMCIVREE commercialization progress are key factors that could influence how the company ultimately performs.

Explore 3 other fair value estimates on Rhythm Pharmaceuticals - why the stock might be worth over 5x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Rhythm Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Rhythm Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Rhythm Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.